A Phase 1/2 interventional study of MIL62 and Cyclosporine in Primary Membranous Nephropathy, sponsored by Beijing Mabworks Biotech Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by Beijing Mabworks Biotech Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Glomerulonephritis, Membranous with a site in China — 29 open to participants now, 37 under way, 10 of them phase 3. Glomerulonephritis, Membranous · China.
Among the 60 studies in Glomerulonephritis, Membranous with a site in China, this one is the 23rd largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2022, is one of 2 in phase 1/2, and was the 23rd registered.
146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.
Browse Glomerulonephritis, Membranous studies →29 of the 60 studies in Glomerulonephritis, Membranous with a site in China are open now. Recruiting first, the newest first:
AstraZeneca · Sites in China, United States, Belgium and 6 more countries
Ages 18–75
Peking University First Hospital · Sites in China
Ages 18–80
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18–75
The First Affiliated Hospital of Air Force Medicial University · Sites in China
Ages 18+
Vertex Pharmaceuticals Incorporated · Sites in China, United States, Australia and 11 more countries
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 14 (34%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 17 · Phase 3 13 · Phase 4 7
First in 1990; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 94 is above the median of 46 across 105 interventional studies indexed under Glomerulonephritis, Membranous.
Median enrollment 77 across the 50 interventional studies, 241 across the 10 observational. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 60 have an industry lead sponsor. The 10 most frequent:
Beijing Mabworks Biotech Co., Ltd. is the lead sponsor of 18 studies on the registry; 11 are open to participants now.
Beijing Mabworks Biotech Co., Ltd. has 2 studies filed under Glomerulonephritis, Membranous — fewer than ten, so there is no comparison to draw.
13 of the studies in Glomerulonephritis, Membranous with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06470191Phase 3Shanghai Jiaolian Drug Research and Development Co., LtdA Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. | 2026-12-31 |
| NCT05707377Phase 3BeOne MedicinesA Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy | 2027-10 |
| NCT06982729Excyte Biopharma LtdStudy of YK012 in Primary Membranous Nephropathy | 2026-12 |
| NCT05668403Shanghai Jiaolian Drug Research and Development Co., LtdA Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy | 2026-12-30 |
| NCT07404436Beijing Friendship HospitalRivaroxaban in Idiopathic Membranous Nephropathy | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 60 studies in Glomerulonephritis, Membranous with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was divided into two stages. In the first stage (Phase Ib), 30 subjects were randomly divided into MIL62 600mg, MIL62 1000mg and cyclosporine groups at a ratio of 1:1:1, with 10 subjects in each group. Tolerance to MIL62 was evaluated within 4 weeks after the first administration. If the overall safety is determined by the investigator and sponsor to be tolerable to MIL62, phase II enrollment will be initiated.
The second stage(Phase II) was also randomly divided into MIL62 600mg, MIL62 1000mg and cyclosporine groups according to the ratio of 1:1:1, 20 subjects in each group, to evaluate the efficacy of MIL62 and cyclosporine in the treatment of primary membranous nephropathy. Eligible subjects in both phases received treatment and follow-up for a total of 104 weeks. The primary efficacy endpoints were the 12-week immune remission rate and the 24-week overall remission rate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MIL62
Drug: Cyclosporine
Drug: MIL62
A 600 mg intravenous (IV) infusion of MIL62 will be administered on Week 1 Day 1 and Week 3 Day 1. If treatment response is observed, additional doses will be administered on Week 25 Day 1 and Week 27 Day 1. According to the protocol amendment in June 2023, some patients also received MIL62 treatment on Week 53 Day 1.
Participants will receive Cyclosporine at a starting oral dose 3.5 mg/kg/d, divided into 2 doses, try to give every 12 hours. The dose was adjusted according to the blood concentration of cyclosporine monitored every 2 weeks ±3 days until the target blood concentration of 125\~175 ng/ mL was reached. Optimized cyclosporine dose will be maintained for a maximum 52 weeks dependent on response and then tapered over 8 weeks.
A 1000 mg intravenous (IV) infusion of MIL62 will be administered on Week 1 Day 1 and Week 3 Day 1. If treatment response is observed, additional doses will be administered on Week 25 Day 1 and Week 27 Day 1. According to the protocol amendment in June 2023, some patients also received MIL62 treatment on Week 53 Day 1.
Stage 1: The Tolerability and Safety of MIL62 in Participants with Primary Membranous Nephropathy
Evaluation of the Tolerability and Safety of MIL62 in Participants with pMN.The tolerance is defined as the occurrence of CTCAE 5.0 Grade ≥3 adverse events within 28 days after the first dose of MIL62.Safety assessments included adverse events, vital signs, physical examinations, laboratory tests, Eastern Cooperative Oncology Group (ECOG) performance status and 12-lead electrocardiograms (ECG) during the study period.
Time frame: up to 2 year after enrollment
Stage 1 and Stage 2: The 12-week immune remission rate in the anti-PLA2R antibody-positive population.
The proportion of participants who achieved immune remission(Anti-PLA2R antibody\<14RU/mL) at week 12.
Time frame: Week 12
Stage 1 and Stage 2:The 24-week overall remission rate (ORR)
The proportion of participants who achieved overall remission (complete and partial remission) at week 24.
Time frame: week 24
Stage 2: The immune remission rate at week 24, 52, 76, and 104.
The proportion of participants who achieved immune remissionat week 24, 52, 76, 104.
Time frame: Week 24, 52, 76 and 104
Stage 2: The complete remission rate (CRR) and partial remission rate (PRR) at week 24.
The proportion of participants who achieved complete remission (CR) and partial remission (PR) at week 24.
Time frame: Week 24
Stage 2:The CRR, PRR and ORR at week 52, 76, 104.
The proportion of participants who achieved CR、PR and overall remission (OR) at week 52,76,104.
Time frame: Week 52, 76, 104
Stage 2: Time to CR and OR
Time frame: up to 104 weeks
Stage 2:The duration of CR and OR
Time frame: up to 104 weeks
Stage 2: Change in anti-PLA2R antibody
Time frame: up to 104 weeks
Stage 2: Change in eGFR
Time frame: up to 104 weeks
Stage 2: Change in 24-hour urine protein
Time frame: up to 104 weeks
Stage 2: Percentage of Participants with Adverse Events (AEs)
Severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0
Time frame: up to 104 weeks
Stage 2: Percentage of participants with AEs of Special Interest (AESIs)
Time frame: up to 104 weeks
Stage 2: Peripheral B-cell Counts at Specified Timepoints.
Time frame: up to 104 weeks
Stage 2: Incidence of ADAs during the study
Time frame: up to 104 weeks
Stage 2: Pharmacokinetic(PK) Parameters during the study: Area Under the Curve(AUC)
Time frame: up to 104 weeks
Stage 2: Pharmacokinetic(PK) Parameters during the study:Maximum Concentration(Cmax)
Time frame: up to 104 weeks
Stage 2: Pharmacokinetic(PK) Parameters during the study: t1/2
Time frame: up to 104 weeks
Stage 2: Pharmacokinetic(PK) Parameters during the study: Volume of Distribution (Vd)
Time frame: up to 104 weeks
Stage 2: Pharmacokinetic(PK) Parameters during the study: Clearance(CL)
Time frame: up to 104 weeks
Ran from Feb 2022 to primary completion in Mar 2025, 36 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anti-CD20 Monoclonal Antibody MIL62
Glomerulonephritis, Membranous →
Beijing Mabworks Biotech Co., Ltd.